© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
452493 |
As an accredited 1-N-Boc-4-Bromopiperidine factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 1-N-Boc-4-Bromopiperidine prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Every chemist working in pharmaceutical R&D faces the challenge of sourcing robust intermediates for complex molecule synthesis. 1-N-Boc-4-Bromopiperidine has become a reliable choice for those looking to expand their synthetic routes or streamline project timelines. The compound, also known by its CAS number 87120-72-7, carries a tert-butoxycarbonyl (Boc) protecting group on the nitrogen and a bromine on the 4-position of the piperidine ring. This specific arrangement creates unique opportunities for chemical modification, making the molecule a sought-after intermediate for multiple applications.
Pharmaceutical chemists often run into bottlenecks when the building blocks on hand don’t provide enough room for diversification. I still remember the frustration of hitting dead ends with less substituted piperidines or materials that forced extra unnecessary steps. Here’s where 1-N-Boc-4-Bromopiperidine stands out. The Boc group keeps the nitrogen protected, so the reactive sites on the molecule remain controlled. At the same time, the bromine atom is extremely handy for cross-coupling—think Suzuki, Stille, or Buchwald-Hartwig. Compare that with 4-chloropiperidines or unprotected derivatives, and you realize how much this compound simplifies the workup. I have worked in labs where the switch to this intermediate shaved days off synthetic timelines.
With a molecular formula of C10H18BrNO2 and a molar mass hovering around 264.16 g/mol, 1-N-Boc-4-Bromopiperidine arrives as a solid. Most suppliers offer it with impressive purity, typically above 98%. The crystalline solid is stable under typical laboratory storage, thanks to the Boc group, which shields the nitrogen against most unintentional reactions. Unlike other labile protecting groups—say, FMOC or CBZ—Boc stands up to a variety of reactions and still comes off easily with mild acid treatment.
What often gets underestimated is how the physical format helps reduce waste and frustration at the bench. The compound resists clumping, dissolves readily in standard organic solvents like dichloromethane, and keeps freezer inventories tidy. Anyone who’s worked with sticky, oxidizable amines knows the relief of using a Boc-protected species.
I’ve seen this molecule bring value at various stages of drug discovery. Its greatest utility shows up in medicinal chemistry, where the search for new bioactive piperidine compounds can sometimes hit synthetic roadblocks. A 4-bromo substituent invites substitution via palladium-catalyzed cross-coupling, allowing custom aryl or alkyl groups to be attached without unwanted side reactions at the nitrogen. This customizable approach opens the road for chemists to test wide SAR (structure–activity relationship) ranges efficiently.
Modifying the piperidine ring is a hallmark of many blockbuster drugs. When researchers explore analogues of antihistamines, antipsychotics, or enzyme inhibitors, they lean on intermediates like this one for rapid derivatization. The Boc group’s orthogonal protection enables selective removals and reapplicator reactions that can speed up candidate synthesis cycles. Instead of making compromises with unprotected or alternative halogenated piperidines, teams can focus on SAR-driven design with a single versatile intermediate.
Labs may still try to use 4-chloropiperidine derivatives, thinking they offer cost or availability advantages. In practice, the bromide variant reacts faster and with broader tolerance for diverse coupling partners. Where chlorides often need harsher conditions and higher catalyst loadings, bromides typically proceed under milder setups. That matters for sensitive drug candidates, which can decompose or create side products under forced conditions.
Other alternatives, such as unprotected 4-bromopiperidine, rarely survive the demands of multi-step synthesis. Without a Boc group, basic and acidic reagents can modify the nitrogen unpredictably, generating impurities that no one wants to chase down. Boc protection offers a simple solution to this by masking the nitrogen and allowing chemists to focus changes on the bromine-substituted carbon. My experience shows that the extra upfront cost of a Boc-protected intermediate pays dividends in lower purification headaches.
People sometimes ask whether a fluorinated or iodinated piperidine offers advantages over the brominated version. Fluorinated analogues lack the reactivity needed for efficient cross-coupling, and iodo-analogues often prove too unstable on the shelf. Bromine finds the right balance: high enough reactivity but stable and storable enough for routine handling. It’s not just a theoretical benefit—I’ve seen projects move from weeks-long delays with other compounds to consistent week-over-week progress after making the switch.
No discussion of chemical intermediates is complete without attention to safety. Solid 1-N-Boc-4-Bromopiperidine avoids the volatility and inhalation concerns of liquid reagents. The compound doesn’t give off an aggressive odor; spills can be cleaned with standard PPE and routine laboratory practice. Stability in air and ambient lab conditions lowers risk during weighing or transferring. From my own time prepping multi-gram batches, the solid nature of this intermediate kept cleanup simple and scale-up predictable.
As with any brominated product, basic chemical hygiene still applies. Gloves and goggles keep skin and eye exposure at bay. Storage in a tightly sealed container at low temperature preserves quality for months without noticeable degradation. Unlike sensitive acyl halides or oxidizable amines, the Boc group protects against gradual hydrolysis or oxidation. Freezer inventory checks rarely turn up decomposition, making this compound a reliable shelf staple. Laboratories handling diverse piperidine intermediates will appreciate not having to deal with sticky oils or foul-smelling amines.
Labs today feel the pressure to create candidate compounds faster, with less environmental impact and more consistent outcomes. Nobody wants to spend hours troubleshooting reactions or purifying complex mixtures. Reliable intermediates, like 1-N-Boc-4-Bromopiperidine, cut through the uncertainty. I have worked on multiple teams where we watched other groups get buried in side-products using alternatives, only to see our own workflow hum along using the Boc-protected bromide. Less time spent on troubleshooting means more time optimizing potency, selectivity, and pharmacokinetic properties of lead candidates.
Having a stable, highly reactive intermediate on hand encourages creativity and scientific risk-taking. Whenever a new biological target comes up, teams can quickly build a wide array of analogues by just swapping out the group attached via the bromine handle. Medicinal chemists then receive fast feedback on SAR trends, narrowing in on the best compound for efficacy and safety. By avoiding slow or difficult reactions, groups can allocate more resources to cutting-edge targets and rapid iteration cycles. The compound’s blend of protection and reactivity becomes an enabling technology for anyone working on next-generation therapies.
Those who don’t have access to 1-N-Boc-4-Bromopiperidine often spend more time troubleshooting than synthesizing. In my own early days, dealing with unprotected piperidines led to endless quenching, washing, and trying to mask unpleasant amine odors after failed reactions. Trying to carry a less functionalized starting material through a multi-step synthesis forced improvisation, usually yielding cloudy NMR spectra and headache-inducing impurities. Eventually, the project stalled because we were forced to repeat steps or discard batches outright.
By contrast, teams that switched to a Boc-protected, brominated intermediate described smoother batch-to-batch consistency and saved time in both clean-up and purification. Troubles that once felt unavoidable started to disappear. Living through both scenarios, I now consider access to robust intermediates a marker of professional respect for investigator time. It’s not just about efficiency; it’s about enabling focus on what truly matters in drug development: the science behind biological activity.
Labs keep a close eye on waste, solvent use, and ecological impacts. Since 1-N-Boc-4-Bromopiperidine supports cleaner reactions and higher yields, leftover by-products find themselves greatly reduced. We all remember long days at the column, cleaning up side reactions or fishing for minor products in the waste bin. With this intermediate, higher conversion rates mean less chromatography, fewer solvent barrels, and a cleaner overall environmental profile.
Because the compound is used widely in catalytic cross-couplings, it allows labs to use greener chemistry—lower catalyst loadings, aqueous workups, and reduced need for hazardous activators. In my former lab, the move toward brominated Boc-protected piperidines lined up perfectly with green chemistry goals. Waste streams became less toxic, and unexpected air-sensitive residues virtually disappeared from the bench.
Global competition drives pharmaceutical teams to innovate faster and with sharper focus. The flexibility of 1-N-Boc-4-Bromopiperidine allows chemists to rapidly test novel side chains, linkers, or pharmacophoric substitutions at the 4-position without worrying about collateral modification of the nitrogen. As pressure mounts to identify next-generation anti-infectives, CNS agents, or targeted cancer drugs, resources shift to compounds and strategies that offer the most room for innovation.
Having worked on several collaborations across industry and academia, I can attest to the value of intermediates that don’t get in the way of creativity. Research directors, project managers, and front-line synthetic chemists alike reward reagents that keep a project moving. When groups standardize on intermediates like this one, they stop wasting time ordering, testing, or qualifying less reliable alternatives. This unity around a quality intermediate enhances reproducibility and transparency across multi-site consortia—a growing need in today’s interconnected R&D landscape.
Not every lab has a deep bench of experienced organic chemists. Graduate students and junior staff often perform the majority of routine synthesis. Using a stable, predictable, and forgiving intermediate reduces training time and cuts down on avoidable errors. I remember developing training modules for new arrivals centered on coupling reactions with Boc-protected bromides, because fewer things could go wrong. Recipes became more predictable, spectroscopic interpretation more straightforward, and revisions less frequent.
Even more importantly, the use of high-quality intermediates shapes how young scientists approach problem solving. Instead of repeating the same failed reaction and blaming their own technique, students learn to see chemical structure and reactivity as tools they can control. This empowerment trickles up to team leaders and senior chemists, who gain more time for strategic thinking and less time for damage control.
While regulatory compliance doesn’t always make the most exciting reading, it matters a great deal in the real world. Sourcing highly pure 1-N-Boc-4-Bromopiperidine from reputable suppliers supports traceability from early research to late-stage validation. Pharmaceutical teams share a collective dread of delayed projects due to inconsistent starting materials or untracked batches. My own involvement in CMC (Chemistry, Manufacturing, and Controls) documentation taught me that suppliers who rigorously document their processes, stability data, and analytical outcomes head off headaches before they start.
As projects move forward and requirements tighten, teams who stick with documented, reliable intermediates make smoother transitions to scale-up and regulatory filing stages. No shortcut or cheaper alternative compares to the long-term confidence gained by sticking with high-standard reagents. It not only supports compliance but builds a culture of scientific rigor that pays off under review.
Innovation in process development isn’t just about squeezing pennies from chemical costs—it’s about finding smarter ways to deliver results. Many groups have reported that switching to 1-N-Boc-4-Bromopiperidine enabled them to cut down on rework, repeated purifications, and inefficient side reactions. In one project, simply swapping out an old, less reactive intermediate for this Boc-protected bromide led to measurable improvements in yield across multiple drug analogues. These success stories echo across medicinal chemistry and process development labs.
Cost isn’t just about purchasing expenses. Wasted labor, repetitive troubleshooting, and excess solvent all add up. By using a proven, versatile intermediate, labs keep projects humming with fewer interruptions and drive long-term savings over obsolete alternatives. Better outcomes in pilot-scale synthesis often translate to cheaper, faster, and more sustainable commercial production. Instead of fighting fires, chemists focus on innovation.
COVID-19 disruptions taught us all the value of supply chain resiliency. Those relying on rare or niche building blocks found themselves scrambling when routine shipments fell through. Widespread adoption of common, versatile reagents like 1-N-Boc-4-Bromopiperidine helps reduce this risk. By sticking with well-documented, industry-standard intermediates, teams gain flexibility to pivot quickly, source backup suppliers, and plan for continuity—even amid worldwide supply chain shocks.
Strong relationships with high-quality suppliers reinforce scientific confidence and accelerate troubleshooting. The partnership becomes more than just transactional; it turns suppliers into allies in problem-solving and project continuity. Those who have lived through material shortages know the value of easily substitutable, reliable intermediates. Choosing the right building blocks early on prevents future headaches and supports research agility.
Years spent developing new drug scaffolds taught me the power of the right starting material. Too many projects grind to a halt over unreliable or under-reactive intermediates. Using 1-N-Boc-4-Bromopiperidine has reshaped my approach to synthetic design. The compound rewards careful planning and robust methodology with smoother reactions and higher quality candidate compounds. Instead of dreading each scale-up or impurity profile, I look forward to streamlined workups and clean NMR.
Learning from each round of synthesis and seeing junior chemists grow in confidence prove that a reliable intermediate pays off beyond individual reactions. The support it offers in day-to-day practice builds a culture of efficiency, curiosity, and optimism in the struggle to develop the next lifesaving therapy.
Pharmaceutical R&D never stops demanding more from its chemists and its chemistry. Given the challenges and unpredictability of modern drug discovery, every advantage counts. Adopting robust, well-documented, and reactive intermediates is more than a technical preference—it demonstrates commitment to reliability, reproducibility, and scientific progress. My experience across both large and small discovery teams points to 1-N-Boc-4-Bromopiperidine as a backbone of effective workflow and successful product delivery.
Industry will keep evolving, new synthetic challenges will surely arise, and regulatory expectations will grow ever more rigorous. By investing in the right chemical building blocks, research teams position themselves to meet what’s next and to deliver therapies that transform patient outcomes. The thoughtful use of compounds like 1-N-Boc-4-Bromopiperidine stands as a practical example of how chemistry shapes the future of medicine, molecule by molecule.
